1. Scrip
  2. >>Business

Big Pharmas Trust To The Science In Zantac Lawsuits

GSK And Sanofi Mount Vigorous Defence

 
• By Kevin Grogan

Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link. 

new gsk logo and hq
GSK Backs 'overwhelming weight of the scientific evidence' behind Zantac • Source: GSK

GSK plc has come out fighting after investors suddenly got nervous about ongoing litigation in the US over the heartburn drug Zantac, sending the UK major's share price down to its lowest level since 2008.

The company developed and launched Zantac (ranitidine) at the beginning of the 1980s and the antiulcerant enjoyed a number of years as the world’s best-selling prescription drug. By the mid-nineties, it became an over-the-counter (OTC) product and as a result of various mergers, ownership was passed between a number of companies including Pfizer Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

 
• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.